Cargando…

Ciprofloxacin exposure and adverse pregnancy outcomes: A Danish nationwide cohort study

OBJECTIVE: To examine the association between maternal exposure to ciprofloxacin and the risk of miscarriage and major malformations. DESIGN: A nationwide register‐based cohort study. SETTING: Data were obtained from the Medical Birth Registry, the National Hospital Registry, the Danish National Pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Noergaard, Mia, Gotfredsen, Ditte Resendal, Sørensen, Anne Mette Skov, Andersen, Jon Trærup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544954/
https://www.ncbi.nlm.nih.gov/pubmed/34954900
http://dx.doi.org/10.1111/1471-0528.17083
_version_ 1784804713256976384
author Noergaard, Mia
Gotfredsen, Ditte Resendal
Sørensen, Anne Mette Skov
Andersen, Jon Trærup
author_facet Noergaard, Mia
Gotfredsen, Ditte Resendal
Sørensen, Anne Mette Skov
Andersen, Jon Trærup
author_sort Noergaard, Mia
collection PubMed
description OBJECTIVE: To examine the association between maternal exposure to ciprofloxacin and the risk of miscarriage and major malformations. DESIGN: A nationwide register‐based cohort study. SETTING: Data were obtained from the Medical Birth Registry, the National Hospital Registry, the Danish National Prescription Registry and Statistics Denmark. POPULATION: Data were collected in the period between 1997 and 2016 and included all registered pregnancies that ended in an elective termination, miscarriage, stillbirth or a live birth. Exposure was defined as redeeming one or more prescriptions of ciprofloxacin. METHODS: Miscarriage was defined as a diagnosis given before 22 weeks without any medical intervention. Major malformations were classified according to EUROCAT 1.4. We matched ciprofloxacin‐exposed pregnancies to unexposed pregnancies on the propensity score in a ratio 1:4. To estimate the hazard ratio (HR) of miscarriage a Cox proportional hazard regression model was used. A log binomial model was used to estimate the relative risk ratio (RR) of major malformations. MAIN OUTCOME MEASURES: HR of miscarriage and the RR of major malformations. RESULTS: A total of 1 650 649 pregnancies were identified. Of these, 10 250 (2050 ciprofloxacin‐exposed) and 6100 (1220 ciprofloxacin‐exposed) were included in the miscarriage and major malformation analysis, respectively. The HR of miscarriage was 0.99 (95% confidence interval [CI] 0.84–1.17). For major malformation, the RR was 1.01 (95% CI 0.72–1.40). For the organ‐specific major malformations and the sensitivity analyses, no significant increased risks were identified. CONCLUSION: We demonstrated no association between miscarriage and maternal ciprofloxacin exposure within the first 22 weeks of pregnancy, or between major malformations and maternal exposure during the first trimester. TWEETABLE ABSTRACT: No association between maternal ciprofloxacin exposure and adverse pregnancy outcomes.
format Online
Article
Text
id pubmed-9544954
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95449542022-10-14 Ciprofloxacin exposure and adverse pregnancy outcomes: A Danish nationwide cohort study Noergaard, Mia Gotfredsen, Ditte Resendal Sørensen, Anne Mette Skov Andersen, Jon Trærup BJOG Research Articles OBJECTIVE: To examine the association between maternal exposure to ciprofloxacin and the risk of miscarriage and major malformations. DESIGN: A nationwide register‐based cohort study. SETTING: Data were obtained from the Medical Birth Registry, the National Hospital Registry, the Danish National Prescription Registry and Statistics Denmark. POPULATION: Data were collected in the period between 1997 and 2016 and included all registered pregnancies that ended in an elective termination, miscarriage, stillbirth or a live birth. Exposure was defined as redeeming one or more prescriptions of ciprofloxacin. METHODS: Miscarriage was defined as a diagnosis given before 22 weeks without any medical intervention. Major malformations were classified according to EUROCAT 1.4. We matched ciprofloxacin‐exposed pregnancies to unexposed pregnancies on the propensity score in a ratio 1:4. To estimate the hazard ratio (HR) of miscarriage a Cox proportional hazard regression model was used. A log binomial model was used to estimate the relative risk ratio (RR) of major malformations. MAIN OUTCOME MEASURES: HR of miscarriage and the RR of major malformations. RESULTS: A total of 1 650 649 pregnancies were identified. Of these, 10 250 (2050 ciprofloxacin‐exposed) and 6100 (1220 ciprofloxacin‐exposed) were included in the miscarriage and major malformation analysis, respectively. The HR of miscarriage was 0.99 (95% confidence interval [CI] 0.84–1.17). For major malformation, the RR was 1.01 (95% CI 0.72–1.40). For the organ‐specific major malformations and the sensitivity analyses, no significant increased risks were identified. CONCLUSION: We demonstrated no association between miscarriage and maternal ciprofloxacin exposure within the first 22 weeks of pregnancy, or between major malformations and maternal exposure during the first trimester. TWEETABLE ABSTRACT: No association between maternal ciprofloxacin exposure and adverse pregnancy outcomes. John Wiley and Sons Inc. 2022-01-17 2022-08 /pmc/articles/PMC9544954/ /pubmed/34954900 http://dx.doi.org/10.1111/1471-0528.17083 Text en © 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Noergaard, Mia
Gotfredsen, Ditte Resendal
Sørensen, Anne Mette Skov
Andersen, Jon Trærup
Ciprofloxacin exposure and adverse pregnancy outcomes: A Danish nationwide cohort study
title Ciprofloxacin exposure and adverse pregnancy outcomes: A Danish nationwide cohort study
title_full Ciprofloxacin exposure and adverse pregnancy outcomes: A Danish nationwide cohort study
title_fullStr Ciprofloxacin exposure and adverse pregnancy outcomes: A Danish nationwide cohort study
title_full_unstemmed Ciprofloxacin exposure and adverse pregnancy outcomes: A Danish nationwide cohort study
title_short Ciprofloxacin exposure and adverse pregnancy outcomes: A Danish nationwide cohort study
title_sort ciprofloxacin exposure and adverse pregnancy outcomes: a danish nationwide cohort study
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544954/
https://www.ncbi.nlm.nih.gov/pubmed/34954900
http://dx.doi.org/10.1111/1471-0528.17083
work_keys_str_mv AT noergaardmia ciprofloxacinexposureandadversepregnancyoutcomesadanishnationwidecohortstudy
AT gotfredsenditteresendal ciprofloxacinexposureandadversepregnancyoutcomesadanishnationwidecohortstudy
AT sørensenannemetteskov ciprofloxacinexposureandadversepregnancyoutcomesadanishnationwidecohortstudy
AT andersenjontrærup ciprofloxacinexposureandadversepregnancyoutcomesadanishnationwidecohortstudy